From the Departments of Pathology (Dr Allen) and Biochemistry (Dr Kurdowska), University of Texas Health Science Center at Tyler. Dr Allen is now located at the University of Texas Medical Branch at Galveston, Texas.
Arch Pathol Lab Med. 2014 Feb;138(2):266-9. doi: 10.5858/arpa.2013-0182-RA. Epub 2013 Jun 19.
Acute lung injury is a complex clinical syndrome involving acute inflammation, microvascular damage, and increased pulmonary vascular and epithelial permeability, frequently resulting in acute respiratory failure culminating in often-fatal acute respiratory distress syndrome. Interleukin 8 (IL-8), a potent neutrophil attractant and activator, plays a significant role in acute lung injury via the formation of anti-IL-8 autoantibody:IL-8 complexes and those complexes' interaction with FcγRIIa receptors, leading to the development of acute lung injury by, among other possible mechanisms, effecting neutrophil apoptosis. These complexes may also interact with lung endothelial cells in patients with acute respiratory distress syndrome. Continuing research of the role of neutrophils, IL-8, anti-IL-8 autoantibody:IL-8 complexes, and FcγRIIa receptors may ultimately provide molecular therapies that could lower acute respiratory distress syndrome mortality, as well as reduce or even prevent the development of acute lung injury altogether.
急性肺损伤是一种涉及急性炎症、微血管损伤和肺血管及上皮通透性增加的复杂临床综合征,常导致急性呼吸衰竭,最终导致常致命的急性呼吸窘迫综合征。白细胞介素 8(IL-8)是一种有效的中性粒细胞趋化因子和激活剂,通过形成抗 IL-8 自身抗体:IL-8 复合物以及这些复合物与 FcγRIIa 受体的相互作用,在急性肺损伤中发挥重要作用,导致急性肺损伤的发展,其机制包括影响中性粒细胞凋亡。这些复合物也可能与急性呼吸窘迫综合征患者的肺内皮细胞相互作用。对中性粒细胞、IL-8、抗 IL-8 自身抗体:IL-8 复合物和 FcγRIIa 受体作用的持续研究,最终可能提供分子治疗方法,降低急性呼吸窘迫综合征的死亡率,并减少甚至预防急性肺损伤的发生。